22-04-2012 15:49 This piece first broadcast on 13 Apr 2012. Televised on UK's satellite television Sky News. Read the original: New treatment for Parkinson's - Video … Continue reading →

23-04-2012 08:05 Chief of neurosurgery G. Rees Cosgrove, MD, discusses the signs and symptoms of Parkinson's Disease and treatment options. Learn more about neurosciences at Rhode Island Hospital: Link: Treating Parkinson's Disease at Rhode Island Hospital - Video … Continue reading →

TORONTO, ONTARIO--(Marketwire -04/23/12)- Cynapsus Therapeutics (TSX-V: CTH.V - News), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced that it has appointed Dr. Abraham Lieberman to its Clinical Advisory Board (CAB). Dr. Lieberman is the Director of the Muhammad Ali Parkinson Center and Movement Disorder Clinic of the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center. The news follows completion of the Company's first human clinical study of APL- 130277, a reformulation of an approved drug (Apomorphine), for the treatment of motor fluctuation in Parkinson's disease. The new appointment enhances the range and depth of expertise of the CAB, which provides medical, clinical and strategic guidance for the Company's product development and commercialization activities. "Cynapsus is very pleased to have Dr. Lieberman join our Clinical Advisory Board. His vast knowledge and commitment to improving treatments and outcomes for Parkinson's patients will be especially valuable as we advance APL -130277 towards clinical practice," said Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "Dr. Lieberman joins an international group of Clinical Advisory Board members, including Dr. Warren Olanow and Dr. Fabrizio Stocchi. Collectively their experience … Continue reading →

Kolkata, Apr 24 : Pharmaceutical and biotechnology major Wockhardt has launched an authorized generic version of four strengths (50mg, 75mg, 125mg and 200mg) of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinsons disease. The Levodopa + Carbidopa + Entacapone tablet is the generic name for the brand Stalevo, owned by Orion Corporation and marketed in the United States by Novartis. Wockhardt launched the product on Monday and is entitled to 180-days of exclusivity. Wockhardt was the first-to-file with paragraph-IV certification on four out of six strengths of this product, said Wockhardt Chairman Dr. Habil Khorakiwala. Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the holder of the NDA, Wockhardt came to an arrangement to launch an authorized generic version with 180-days of exclusivity. The product involved development of a complex API as well as a triple-drug combination formulation, he said. Incidence of Parkinsons disease is increasing worldwide. According to IMS Health, the total market for this product in the US is about USD 55 million for the above four strengths and even after the 180-days exclusivity the number of competitors to enter the market is expected to … Continue reading →

New Delhi, Apr 24: Wockhardt said on Tuesday that it has launched a generic version of Orion Corporations Parkinsons treatment drug Stalevo in the US, with 180 days of marketing exclusivity. The company said its generic copy is of four strengths (50mg, 75mg, 125mg and 200mg) of the triple drug combination product containing levodopa, carbidopa and entacapone. Wockhardt was the firsttofile with paragraph IV certification on four out of six strengths of this product, Wockhardt Chairman, Mr Habil Khorakiwala, said in a statement. Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the two parties came to an arrangement to launch an authorised generic version with 180 days of exclusivity, he added. Wockhardt launched the product on April 23, 2012 and is entitled to 180 days of exclusivity, the company said. The combination of levodopa, carbidopa and entacapone tablet is the generic name for the brand Stalevo, owned by Orion Corporation and marketed in the US by Novartis. Citing IMS Health, Wockhardt said the total market for this product in the US is about $ 55 million for the above four strengths and even after the 180 days exclusivity the number of competitors to enter the … Continue reading →